Shanghai Pharmaceutical Co., Ltd. has announced that it will withdraw from drug R&D and concentrate its resources on drug distribution, a business it has been leading domestically for nine years. The company will transfer its 19.66 percent stake in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and inject 6.5 million yuan to its holding company Shanghai Waigaoqiao Pharmaceutical Business And Distribution Center. However, Shanghai Pharmaceutical will not give up its original equipment manufacturing business, which gives a return on investment of 27.5 percent. It will renovate Tianping Pharmaceutical Factory's machining workshop to carry out OEM for U.S. Perrigo. (Click here for more - Chinese Language)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
